home / stock / alpmf / alpmf short
Short Information | Astellas Pharma Inc (OTCMKTS:ALPMF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 10,592 |
Total Actual Volume | 77,029 |
Short Trends | |
---|---|
Cover Days | 10 |
Short Days | 10 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 530 |
Average Short Percentage | 50.14% |
Is there a ALPMF Short Squeeze or Breakout about to happen?
See the ALPMF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-15-2024 | $10.49 | $10.4 | $10.49 | $10.4 | 311 | 211 | 67.85% |
07-11-2024 | $10.3 | $10.29 | $10.3 | $10.29 | 26,580 | 1,860 | 7% |
06-24-2024 | $0 | $9.35 | $0 | $0 | 315 | 65 | 20.63% |
06-20-2024 | $9.8 | $9.35 | $9.8 | $9.25 | 2,400 | 525 | 21.88% |
06-10-2024 | $0 | $9.621 | $0 | $0 | 68 | 1 | 1.47% |
05-22-2024 | $10.02 | $10.02 | $10.02 | $10.02 | 1,600 | 200 | 12.5% |
05-21-2024 | $9.92 | $9.92 | $9.92 | $9.92 | 9,904 | 500 | 5.05% |
05-20-2024 | $10 | $10 | $10 | $10 | 400 | 400 | 100% |
05-17-2024 | $9.56 | $9.56 | $9.56 | $9.56 | 250 | 250 | 100% |
05-14-2024 | $9.5 | $10.02 | $10.02 | $9.5 | 1,726 | 25 | 1.45% |
05-03-2024 | $0 | $9.521 | $0 | $0 | 60 | 60 | 100% |
04-25-2024 | $9.6 | $9.8414 | $9.8414 | $9.6 | 22,820 | 2,500 | 10.96% |
04-16-2024 | $9.13 | $9.594 | $9.594 | $9.13 | 2,166 | 250 | 11.54% |
04-12-2024 | $9.59 | $9.48 | $9.59 | $9.48 | 1,720 | 1,200 | 69.77% |
03-27-2024 | $10.83 | $11.165 | $11.165 | $10.83 | 900 | 500 | 55.56% |
03-21-2024 | $0 | $11.09 | $0 | $0 | 50 | 50 | 100% |
03-20-2024 | $0 | $11.09 | $0 | $0 | 90 | 90 | 100% |
03-19-2024 | $11.26 | $11.09 | $11.26 | $10.58 | 4,544 | 780 | 17.17% |
03-18-2024 | $11.31 | $11.31 | $11.31 | $11.31 | 925 | 925 | 100% |
03-13-2024 | $10.74 | $10.74 | $10.74 | $10.74 | 200 | 200 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...